Drug discovery - Articles - Page 7

Abcellera scientist prepares reagents in lab

Abcellera IPO rockets upward with $555.5M in gross proceeds

Dec. 28, 2020

TORONTO – It took the Vancouver, British Columbia-based biotech three times, but before the week in mid-December was over, Abcellera Biologics Inc. had finally closed its IPO on the Nasdaq, hoovering up gross proceeds of $555.5 million.

Phar-East 2020 virtual conference looks at tech and transformation

Dec. 15, 2020

By David Ho

New approaches to trials, digitalization and the effective use of technologies like artificial intelligence are reshaping how clinical trials are conducted, drugs are discovered, and devices are developed.

Phar-East 2020 virtual conference looks at tech and transformation

Dec. 9, 2020

By David Ho

HONG KONG – New approaches to trials, digitalization and the effective use of advance technologies like artificial intelligence are reshaping how clinical trials are conducted, drugs are discovered, and new devices are developed, said participants at the Asia-focused Phar-East 2020 conference on Dec. 8.

Nvidia investing $52M in U.K. supercomputer for drug discovery

Oct. 5, 2020

By Nuala Moran

LONDON – U.S. chipmaker Nvidia Inc. is investing £40 million (US$51.9 million) in building a supercomputer in Cambridge, U.K., to be dedicated to applying artificial intelligence in drug discovery and in health care.

2020 KoNECT-MOHW-MFDS International Conference

SK C&C looks to AI to enhance Korean drug discovery process

Sep. 15, 2020

By Gina Lee

HONG KONG – The Korean 2020 KoNECT-MOHW-MFDS International Conference, which is taking place online this year due to the COVID-19 pandemic, faced a challenging start. Technical difficulties hampered some of the early proceeding. However, technology took focus again later in the day in a more positive, with an exploration of artificial intelligence (AI).

2020 KoNECT-MOHW-MFDS International Conference

Implementing AI in the drug discovery process is difficult but not impossible

Sep. 15, 2020

By Gina Lee

HONG KONG – The use of artificial intelligence in drug discovery was back in the spotlight on the last day of the 2020 KoNECT-MOHW-MFDS International Conference, with drug developers pointing out both challenges and possible solutions.

2020 KoNECT-MOHW-MFDS International Conference

Implementing AI in the drug discovery process is difficult but not impossible

Sep. 11, 2020

By Gina Lee

HONG KONG – The use of artificial intelligence in drug discovery was back in the spotlight on the last day of the 2020 KoNECT-MOHW-MFDS International Conference, with drug developers pointing out both challenges and possible solutions.

2020 KoNECT-MOHW-MFDS International Conference

SK C&C looks to AI to enhance Korean drug discovery process

Sep. 9, 2020

By Gina Lee

HONG KONG – The Korean 2020 KoNECT-MOHW-MFDS International Conference, which is taking place online this year due to the COVID-19 pandemic, faced a challenging start. Technical difficulties hampered some of the early proceeding. However, technology took focus again later in the day in a more positive, with an exploration of artificial intelligence (AI).

Takeda, Engitix ink $500M deal for liver fibrosis therapy

Sep. 1, 2020

By Nuala Moran

LONDON – Engitix Ltd has secured Takeda Pharmaceutical Co. Ltd.’s endorsement of its extracellular matrix (ECM) technology in a potential $500 million deal in liver fibrosis.

Takeda, Engitix ink $500M deal for liver fibrosis therapy

Aug. 25, 2020

By Nuala Moran

LONDON – Engitix Ltd has secured Takeda Pharmaceutical Co. Ltd.’s endorsement of its extracellular matrix (ECM) technology in a potential $500 million deal in liver fibrosis.